| Name | benserazide |
| Synonyms | benserazide BENOXACOR CHEM-1468 evodopa and Benserazide 2-(2,3,4-trihydroxybenzyl)hyrazide,dl-serin 2-aMino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide 2-Amino-3-Hydroxy-2'-(2,3,4-Trihydroxybenzyl)Propionohydrazide 2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propionohydrazide 2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide 2-azanyl-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide 2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide (non-preferred name) |
| CAS | 322-35-0 |
| EINECS | 1312995-182-4 |
| InChI | InChI=1/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18) |
| Molecular Formula | C10H15N3O5 |
| Molar Mass | 257.24 |
| Density | 1.541±0.06 g/cm3(Predicted) |
| Boling Point | 574.2±50.0 °C(Predicted) |
| Flash Point | 301°C |
| Vapor Presure | 5.06E-14mmHg at 25°C |
| pKa | 9.40±0.40(Predicted) |
| Refractive Index | 1.678 |
| Physical and Chemical Properties | Oral absorption is fast, absorption rate of about 58%, in the intestine metabolism, excretion by the urine, 12 hours excretion of about 90%. General benserazide and levodopa according to 1: 4 compatibility application. |
| Use | It is a peripheral dopa decarboxylase inhibitor and acts like Carbidopa. |
| Hazard Symbols | Xi - Irritant![]() |
| Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
| Pharmacokinetics | Oral absorption is fast and incomplete, the absorption rate is about 58%, and it does not penetrate the blood-brain barrier. Metabolized in the intestine, excreted by urine, about 90% excreted in 12 hours. Generally, this product is used in a 1:4 compatibility with levodopa. For paralytic tremor. |
| adverse reactions | combined with levodopa, side effects are reduced, sometimes insomnia, restlessness and other symptoms can be seen, and chorea-like symptoms can be seen in the late treatment. |
| preparations and specifications | dopa hydrazine capsules (madopa, madopa):125mg [levodopa 100mg and benserazide 25mg (equivalent to benzserazide hydrochloride 28.5mg)], 250mg [levodopa 200mg and benserazide 50mg (equivalent to benzserazide hydrochloride 57mg)]. |
| Uses | Used for neuropharmacological and physiological research to inhibit dopamine decarboxylation. It is a peripheral dopa decarboxylase inhibitor, which acts like carbidopa. |
| Production method | It is obtained by reacting 2,3, 4-trihydroxytoluene and DL-seroyl hydrazide hydrochloride as raw materials. |